

Iph

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant : Chikara MURAKATA et al.

Confirmation No. 89888

Serial No. : 10/553,222
(National Stage of PCT/JP2004/005489)

Group Art Unit: 1626

I.A. Filed : April 16, 2004

Examiner: R. HAVLIN

For : MITOTIC KINESIN INHIBITOR

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§ 1.97-1.98, and supplemental to the Information Disclosure Statements previously filed on September 1, 2006; April 10, 2007; May 10, 2007; and September 8, 2008, Applicants direct the Examiner's attention to the following documents cited in the Supplementary Partial European Search Report for European Application No. EP 04 72 8012, of which the above-referenced application is a family member application:

- (1) WO 2004111023 A1, Applicants note that this document was cited and listed in the Third Supplemental Information Disclosure Statement filed September 8, 2008;
- (2) EP 1 632 484 A1, March 8, 2006;

- (3) U.S. Application No. 10/560,230 to MURAKATA et al., entitled "Thiadiazoline Derivative", filed June 9, 2004, and published as U.S. Patent Application Publication No. 2007/0276017 A1, November 29, 2007; Applicants note that this document is a family member of document (2); and
- (4) EP 1 671 957 A1, June 21, 2006; Applicants note that this document is a family member of US Application No. 10/575,093 (published as US 2007/0112044 A1, May 17, 2007), which was cited and listed in the Supplemental Information Disclosure Statement filed April 10, 2007.

Copies of documents (2) and (4), and the Supplementary Partial European Search Report for European Application No. EP 04 72 8012 are enclosed together with a completed copy of the Form PTO-1449 listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the Form PTO-1449 with the next communication.


Further to 37 C.F.R. §1.98 (a)(2)(ii) and the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(iii) if the U.S. patent application was filed after June 30, 2003, copies of the U.S. patent applications cited above are not enclosed herewith. However, if any copy is needed, the Examiner is respectfully requested to contact the undersigned.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if

an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there are any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Chikara MURAKATA et al.



Bruce H. Bernstein
Reg. No. 29,027 42,920

November 14, 2008
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191